[ { "report_key": "2026:q1", "period_label": "2026 Q1", "date": "2026-05-06", "title": "Kvartalsrapport Q1 2026", "original_title": "Delårsrapport januari - mars 2026", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b00c6b9419fef5bc28396a5eea3441408&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a17a9a42943519ac9b9499fe483dd8fb0", "date": "2026-05-06", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "Delarsrapport_Q1_2026.pdf", "text_chars": 43334, "sha256": "09147e95128f9573312939d88e4cd55ef0f44869b0d6c2e67669fdb18de078a2", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 43334 } ] } ], "alternatives": [] }, { "report_key": "2025:annual", "period_label": "2025 Årsredovisning", "date": "2026-03-26", "title": "Årsredovisning 2025", "original_title": "Vicore offentliggör årsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b600d68604b5fc3eac062c3954b408421&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac8734d7900ed05a77157d57e58b8b371", "date": "2026-03-26", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "Vicore_Arsredovisning_2025.pdf", "text_chars": 264632, "sha256": "cf21b11fe94cda4920e011e4e767df699b1349e5f5e2c869b360c68369924dd6", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 177351 }, { "number": 2, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-002.html", "chars": 87279 } ] } ], "alternatives": [] }, { "report_key": "2025:q4", "period_label": "2025 Q4", "date": "2026-02-27", "title": "Kvartalsrapport Q4 2025", "original_title": "Bokslutskommuniké 2025", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b72784e8b83c8522ce08632a00a87ef39&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/afd2d355616d2dcdf9003f1247ed96a80", "date": "2026-02-27", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "Bokslutskommunike_2025.pdf", "text_chars": 48919, "sha256": "7e4a990abee0deb5b338104e95f47947087f925b89faba7d499c506c37cc4b57", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 48919 } ] } ], "alternatives": [] }, { "report_key": "2025:q3", "period_label": "2025 Q3", "date": "2025-11-05", "title": "Kvartalsrapport Q3 2025", "original_title": "Delårsrapport juli-september 2025", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b7db3aa72a81418db70ff496c131bfcc0&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a29e802aad5879985f414115f16438495", "date": "2025-11-05", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "Delarsrapport_Q3_2025.pdf", "text_chars": 51972, "sha256": "0e5199bb265cc9be60565f6340f00d5a45b86ab1b999286b68a23102291bd697", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 51972 } ] } ], "alternatives": [] }, { "report_key": "2025:q2", "period_label": "2025 Q2", "date": "2025-08-22", "title": "Kvartalsrapport Q2 2025", "original_title": "Delårsrapport april-juni 2025", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b97f6d13a90c2672b76c146ae640a80cb&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a601e14263c6a6dcc72f09a601e5b2ca5", "date": "2025-08-22", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "Delarsrapport_Q2_2025.pdf", "text_chars": 46643, "sha256": "4f5e331a70cc9772f9dd39e6df020504fac3d16ca61251bf208d4a16873d736a", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 46643 } ] } ], "alternatives": [] }, { "report_key": "2025:q1", "period_label": "2025 Q1", "date": "2025-05-06", "title": "Kvartalsrapport Q1 2025", "original_title": "Delårsrapport januari-mars 2025", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b3054c17c4a86c0f5b08a02f0e9590b1e&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad1ca81c15c657972c0cbda55b9a6cf97", "date": "2025-05-06", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "Delarsrapport_1_Jan_31_Mar_2025.pdf", "text_chars": 45176, "sha256": "161203666816ea945e02334a7230bae78a4e1ea2e6b137545068c9a8eaa7c3c3", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 45176 } ] } ], "alternatives": [] }, { "report_key": "2024:annual", "period_label": "2024 Årsredovisning", "date": "2025-03-26", "title": "Årsredovisning 2024", "original_title": "Vicore offentliggör årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bdd4d68888e865bc214adcdd4677b1d08&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a66794ceb802528c55ffb3b1ee8c7dc30", "date": "2025-03-26", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "Vicore_Arsredovisning_2024.pdf", "text_chars": 287791, "sha256": "e628a6484cb38d6916f50f4bc7eb4107854107a6b4209198279eeffc4e890f83", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 177393 }, { "number": 2, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-002.html", "chars": 110396 } ] } ], "alternatives": [] }, { "report_key": "2024:q4", "period_label": "2024 Q4", "date": "2025-02-27", "title": "Kvartalsrapport Q4 2024", "original_title": "Bokslutskommuniké 2024", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b360b480bb9fc49e165fd522b72bf1b42&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae73c8303818455588695b9a0c1a06058", "date": "2025-02-27", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "Bokslutskommunike_2024_SWE.pdf", "text_chars": 49883, "sha256": "d4ea4a7ef8edb2a85eb7b43efde15f54c7399e3b60bc62edffc2942f1effadfd", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 49883 } ] } ], "alternatives": [] }, { "report_key": "2024:q3", "period_label": "2024 Q3", "date": "2024-11-05", "title": "Kvartalsrapport Q3 2024", "original_title": "Delårsrapport juli-september 2024", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=ba1091d4997b1ad6a448ff25af01915e0&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a5e2cc4eb1aa5dacb7918657cd4a93246", "date": "2024-11-05", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "Delarsrapport_Q3_2024.pdf", "text_chars": 50324, "sha256": "d71acb6909f6dc0064559b9d5eada617dc7a5aa63bb83175f56d6ad761982ba0", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 50324 } ] } ], "alternatives": [] }, { "report_key": "2024:q2", "period_label": "2024 Q2", "date": "2024-08-22", "title": "Kvartalsrapport Q2 2024", "original_title": "Delårsrapport april-juni 2024", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b8e0088e8cb4bbbc4bdd222a8d48f4385&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac33a252ae1cac6377103173b7acabf2c", "date": "2024-08-22", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "Delarsrapport_Q2_2024.pdf", "text_chars": 44660, "sha256": "b1aba9ecf5644930cba10892b99fbd6453b3cb18fcd3bba129bfe31e5a67ade5", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 44660 } ] } ], "alternatives": [] }, { "report_key": "2024:q1", "period_label": "2024 Q1", "date": "2024-05-03", "title": "Kvartalsrapport Q1 2024", "original_title": "Delårsrapport januari-mars 2024", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b07abb63329fd21adf8d4a9f2ba0e3bb6&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aacba62192026d1de39a5f33b4daf9986", "date": "2024-05-03", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "Delarsrapport_Q1_2024_FINAL.pdf", "text_chars": 41479, "sha256": "4bb721d5cd96b117a2187fe95d2cbeaeb4ef1620ebcc885308a87e4feba34f5d", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 41479 } ] } ], "alternatives": [] }, { "report_key": "2023:annual", "period_label": "2023 Årsredovisning", "date": "2024-03-27", "title": "Årsredovisning 2023", "original_title": "Vicore offentliggör årsredovisning för 2023", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bd7b3e65ea8ded43a8959cfcf5981d5eb&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a2ae7c68718235fae332b816f53ab1738", "date": "2024-03-27", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "Vicore_Arsredovisning_2023.pdf", "text_chars": 269652, "sha256": "8cd42f435d0f31bff067af1f3f30fc1a7412f89d76ced868bea0929d79c6716a", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 179110 }, { "number": 2, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-002.html", "chars": 90540 } ] } ], "alternatives": [] }, { "report_key": "2023:q4", "period_label": "2023 Q4", "date": "2024-02-28", "title": "Kvartalsrapport Q4 2023", "original_title": "Bokslutskommuniké 2023", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b5cb03fd0542c64e01c883b37cd1f5acd&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad4f6a640bbf90aa0f94b72149a909dbd", "date": "2024-02-28", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "Bokslutskommunike_2023.pdf", "text_chars": 45516, "sha256": "f652188f84d1a7e121c4fd947d8c3929e298979d50634fa8ca98838242c02eab", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 45516 } ] } ], "alternatives": [] }, { "report_key": "2023:q3", "period_label": "2023 Q3", "date": "2023-11-02", "title": "Kvartalsrapport Q3 2023", "original_title": "Delårsrapport juli-september 2023", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b2c54299bcf62d6367d586a5c4588c58f&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a0e437a99b9af6d9ca3735b061af97537", "date": "2023-11-02", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "Delarsrapport_Q3_2023.pdf", "text_chars": 43926, "sha256": "3344bafc5252080871c96ece9a38f5b51c9d7b3b10a360129f1a7bef78146d4d", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 43926 } ] } ], "alternatives": [] }, { "report_key": "2023:q2", "period_label": "2023 Q2", "date": "2023-08-24", "title": "Kvartalsrapport Q2 2023", "original_title": "Delårsrapport april-juni 2023", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b9c1e213206b463347e49c17c1c83df25&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ade8c9e5626a289c75d0d5612b408bc0b", "date": "2023-08-24", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "Delarsrapport_April_Juni_2023.pdf", "text_chars": 42123, "sha256": "fc851ed2d2aaaac8bab7199536d85cdbc693257f10bbf79d95a307b89d767da2", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 42123 } ] } ], "alternatives": [] }, { "report_key": "2023:q1", "period_label": "2023 Q1", "date": "2023-05-04", "title": "Kvartalsrapport Q1 2023", "original_title": "Rättelse: Delårsrapport januari-mars 2023", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b135579da42267f8c35aef4506d1d7e46&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a4a08c7c7e1a6de7650f7cc53f699d9bf", "date": "2023-05-04", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "Delarsrapport_Jan_Mar_2023.pdf", "text_chars": 39808, "sha256": "8e7ec395406e329278366eab28393e92de4ec1fbc55fc025a82ed1d7356fea5b", "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 39808 } ] } ], "alternatives": [] } ]